Efficient induction of local and systemic antitumor immune response by liposome-mediated intratumoral Co-transfer of interleukin-2 gene and interleukin-6 gene

Journal of Experimental and Clinical Cancer Research

Volumn 18, Issue 2, 1999, Pages 191-200

  Cao, X ^a   Wang, Q ^a   Ju, D W ^a   Tao, Q ^a   Wang, J ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor immunity; Gene therapy; Interleukin 2; Interleukin 6; Liposome

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; LIPOSOME; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLASMID DNA; TUMOR NECROSIS FACTOR; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DNA TRANSFER; DRUG EFFICACY; DRUG POTENCY; GENE THERAPY; INTRATUMORAL DRUG ADMINISTRATION; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELLULAR IMMUNITY; CYTOLOGY; EXPERIMENTAL MELANOMA; GENE TRANSFER; GENETICS; IMMUNOLOGY; INTRALESIONAL DRUG ADMINISTRATION; METABOLISM; MUSCLE TUMOR; SPLEEN; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; CYTOKINES; GENE THERAPY; GENE TRANSFER TECHNIQUES; IMMUNITY, CELLULAR; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; INTERLEUKIN-6; LIPOSOMES; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MUSCLE NEOPLASMS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032589101     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Caligiuri M.A., Murray C., Robertson M.J., Wang E., Cochran K., Cameron C., Schow P., Ross M.E., Klumpp T.R., Soiffer R.J., Smith K.A., Ritz J.: Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J. Clin. Invest. 1993; 91:123-132.
2. Rosenberg S.A., Yang J.C., Popalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Eihorn J.H., White D.E.: Treatment of 283 consecutive patients wit metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-913
3. Janssen R.A., Muller N.H., The T.H., Leij L.: The immunobiological effects if interleukin-2 in vivo. Cancer Immunol. Immunother. 1994;39:207-216
4. Legha S.S., Gianan M.A., Eton O.E., Papadopoulous N.E.J.: Evaluation of interleukin-2 administrated by continuous infusion in patients with metastatic melanoma. Cancer 1996; 77:89-96
5. Sznol M. and Parkinson D.R.: Interleukin-2 in therapy of hematologic malignancies. Blood 1994;83:2020-2022
6. Kishimoto T.: The biology of interleukin-6. Blood 1989;74:1-10.
7. Mule J.J., Custer M.C., Travis W.D., Rosenberg S.A.: Cellular mechanisms of antitumor activity of recombinant IL-6 in mice. J. Immunol. 1992;148:2622-2629.
8. Katz A., Shulman L.M., Porgador A., Revel M., Feldman M., Eisenbach L.: Abrogation of B16F10 melanoma metastases by long-term low-dose interleukin-6 therapy. J. Immunother. 1993;13:98-109.
9. Katz A., Shulman L.M., Revel M., Feldman M., Eisenbach L.: Combined therapy with IL-6 and inactivated tumor cells suppresses metastasis in mice bearing 3LL lung carcinomas. Int. J. Cancer 1993;53:812-818.
10. Plautz G.E., Yang Z.Y., Wu B.Y., Gao X., Huang L., Nabel G.J.: Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. USA 1993;90:4645-4649
11. Vieweg J., Rosenthal F.M., Bannerji R., Heston W.D.W., Fair W.R., Bansbacher B., Gilboa E.: Immunotherapy of prostate cancer in the dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. 1994;54:1760-1765.
12. Bannerji R., Arroyo C.D., Cordon-Cardo C., Gilboa E.: The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J. Immunol. 1994; 152:2324-2332
13. Cao X., Zhang W., Yu Y., Tao Q., Ye T.: Induction of antitumor immunity and treatment of pre-established tumors by interleukin-6-gene-transfected melanoma cells combined with low-dose IL-2. J. Cancer. Res. Clin. Oncol. 1995;121:721-728
14. Cao X., Chen G., Zhang W., Yu Y., Ye T.: Enhanced efficacy of combination of IL-2 gene and IL-6 gene-transfected tumor cells in the treatment of established metastatic tumors. Gene Ther. 1996;3:421-426
15. Dranoff G., Faffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 1993;90:3539-3543.
16. Dougherty G.J., Thacker J.D., Lavey R.S., Belldegrun A., McBride W.H.: Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growth in vivo. Cancer Immunol. Immunother. 1994;38:339-345.
17. Hirai H., Satoh E., Osawa M., Inaba T., Shimazaki C., Kinoshita S., Nakagawa M., Mazda O., Imanishi J.: Use of EBV-based Vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms. Biochem. Biophys. Res. Commun. 1997;241:112-118
18. Knowles M.R., Noone P.G., Hohneker K., Johnson L.G., Boucher R.C., Efthimiou J., Crawford C., Brown R., Schwartzbach C., Pearlman R.: A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis. Hum. Gene Ther. 1998;9:249-269
19. Nabel G.J., Gordon D., Bishop D.K., Nickoloff B.J., Yang Z.Y., Aruga A., Cameron M.J., Nabel E.G., Chang A.E.: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. USA 1996;93:15388-15393
20. Hui K.M., Ang P.T., Huang L., Tay S.K.: Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. Gene Ther. 1997;4:783-790
21. Egilmez N.K., Cuenca R., Yokota S.J., Sorgi F., Bankert R.B.: In vivo cytokine gene therapy of human tumor xenografts in SCID mice by liposome-mediated DNA delivery. Gene Ther. 1996; 3: 607-614
22. Smyth M.J., Ortaldo J.R.: Comparison of the effect of IL-2 and IL-6 on the lytic activity of purified human peripheral blood large granular lymphocytes. J. Immunol. 1991; 146: 1380-1384.
23. Rock F., Everett M., Klein M.: Overexpression and structure-function analysis of a bioengineered IL2/IL-6 chimeric lymphokine. Protein Engineering 1992;5:583-591.
24. Karasuyama H., Melchers F.: Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4, or 5, using modified cDNA expression vectors. Eur. J. Immunol. 1988;18:97-104
25. Szoka F. Jr., Papahadjopoulos D.: Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc. Natl. Acad. Sci. USA 1978;75:4194-4198
26. Zhao D.D., Watarai S., Lee J.T., Kouchi S., Ohmori H., Yasuda T.: Gene transfection by cationic liposomes: comparison of the transfection efficiency of liposomes prepared from various positively charged lipids. Acta Med. Okayama 1997;51:149-154
27. Dass C.R., Walker T.L., Burton M.A., Decruz E.E.: Enhanced anticancer therapy mediated by specialized liposomes. J. Pharm. Pharmacol. 1997;49:972-975
28. Song Y.K., Liu F., Chu S., Liu D.: Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration. Hum. Gene Ther. 1997;8:1585-1594
29. Filion M.C., Phillips N.C.: Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim. Biophys. Acta 1997; 1329:345-356
30. Radler J.O., Koltover I., Salditt T., Safinya C.R.: Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes. Science 1997 ;275: 810-814
31. Katsanis E., Orchard P.J., Bausero M.A., Gorden K.B., McIvor R.S., Blazar B.R.: Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of pre-established retroperitoneal tumors. J Immunother, 1994;15:81-90.
32. Gansbacher B., Zier K., Cronin K., Hantzopoulos A., Bouchard B., Houghton A., Bilboa E., Golde D.: Retroviral gene transfer induced constitutive expression of IL-2 or IFN-gamma in irradiated human melanoma cells. Blood 1992; 80:2817-2822.
33. Bui L.A., Butterfield L.H., Kim J.Y., Ribas A., Seu P., Lau R., Glaspy J.A., McBride W.H., Economou J.S.: In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum. Gene Ther. 1997; 8: 2173-2182
34. Kopantzev E., Roschke V., Rudikoff S.: Interleukin-2-mediated modulation of plasma cell tumor growth in a model of multiple myeloma. Hum. Gene Ther. 1998;9:13-19
35. Simova J., Bubenik J., Jandlova T., Indrova M.: Irradiated IL-2 gene-modified plasmacytoma vaccines are more efficient than live vaccines. Int. J. Oncol. 1998;12:1195-1198
36. Vlk V., Rossner P., Indrova M., Bubenik J., Sobota V.: Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int. J. Cancer. 1998;76:115-119
37. Mullen C.A., Coale M.M., Levy A.T., Stetler-Stevenson W.G., Liotta L.A., Brandt S., Blaese R.M.: Fibrosarcoma cells transduced with IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity and decreased metastatic potential. Cancer Res. 1992;52:6020-6024.
38. Ohe Y., Podack E.R., Olsen K.J., Miyahara Y., Miura K., Saito H., Koishihara Y., Ohsugi Y., Ohira T., Nishio K., Saijo N.: Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shorten survival in syngenic mice. Br. J. Cancer 1993; 67:939-944.
39. Porgador A., Tzehoval E., Katz A., Vadai E., Revel M., Feldman M., Eisenbach L.: Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 1992;52:3679-3686.
40. Tanaka F., Abe M., Akiyoshi T., Nomura T., Sugimachi K., Kishimoto T., Suzuki T., Okada M.: The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res. 1997;57:1335-1343
41. Ohe Y., Podack E.R., Olsen K.J., Miyahara Y., Ohira T., Miura K., Nishio K., Saijo N.: Combination effect of vaccination with IL-2 and IL-4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells. Int. J. Cancer 1993;53:432-437.
42. Ohira T., Ohe Y., Heike Y., Podack E.R., Olsen K.J., Nishio K., Nishio M., Miyahara Y., Funayama Y., Ogasawara H.: Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline. Gene Ther. 1994;1:269-275
43. Vyth-Dreese F.A., Dellemijn T.A., Frijhoff A., van Kooyk Y., Figdor C.G.: Role of LFA-1/ICAM-1 in interleukin-2-stimulated lymphocyte proliferation. Eur. J. Immunol. 1993; 23: 3292-3299
44. De Giovann C., Palmieri G., Nicoletti G., Landuzzi L., Scotlandi K., Bontadini A., Tazzari P.L., Sensi M., Santoni A., Nanni P., Lollini P.L.: Immunological and non-immunological influence of H-2Kb gene transfection on the metastatic ability of B16F10 melanoma cells. Int. J. Cancer 1991;48:270-276.
45. Rosenthal F.M., Cronin K., Bannerji R., Golde D.W., Gansbacher B. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs. Blood 1994;83:1289-1298.
46. Lorr K., Kamme J.V., Verwilghen J., Baroja M.L., Ceuppens J.L.: IL-6 is an accessory signal in the alternative CD2-mediated pathway of T cell activation. J. Immunol. 1990;144:4681-4687.
47. Luger T.A., Krutmann J., Kirnbauer R., Urbanski A., Schwarz T., Klappacher G., Kock A., Micksche M., Malejczyk J., Schauer E.: IFN-beat2/IL-6 augments the activity of human natural killer cells. J. Immunol. 1989;143:1206-1209.
48. Musso T., Espinoza-Delgado I., Pulkki K., Gusella G.L., Longo D.L., Varesio L.: IL-2 induces IL-6 production in human monocytes. J. Immunol. 1992;148:795-800.